Partner Julie Tibbets shares why generic drug makers and marketers must carefully adhere to the U.S. Food and Drug Administration’s requirements for promoting drug products and why knowing common pitfalls is so important to avoiding regulatory scrutiny and ensuring compliant promotional conduct.
Read the full article.
Related Content
- AlertApril 25, 2024
FTC Issues Final Rule Prohibiting Most Post-Employment Non-Compete Agreements
- Life Sciences PerspectivesApril 23, 2024
The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years
- Life Sciences PerspectivesApril 23, 2024
Recap: Goodwin Rare Disease Symposium 2024
- Big Molecule WatchApril 23, 2024
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar
- Big Molecule WatchApril 22, 2024
DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing
- Big Molecule WatchApril 22, 2024
Federal Circuit Dismisses Appeals in Regeneron v. Mylan (Aflibercept) BPCIA Litigation
- AlertApril 22, 2024
The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years
- Big Molecule WatchApril 19, 2024
Fresenius Kabi Announces Launch of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRA
- Press Release29 April 2024
Amid Continued Growth in the United Kingdom, Goodwin Relocates London Office to Iconic Paternoster Square
- Press ReleaseApril 23, 2024
Allurion Technologies Completes $48 Million Convertible Senior Secured Note Financing with RTW Investments
- Press ReleaseApril 22, 2024
Sound Bioventures joins £19 Million Financing of Theolytics
- In the PressApril 22, 2024
PowerUp 4 - Omer Tene (Spotify)
- Awards and RankingsApril 18, 2024
Goodwin is Number One in the Q1 2024 League Table Rankings
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
- Press ReleaseApril 16, 2024
Goodwin Represents the Underwriters in PACS Group $450 Million IPO